Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03009981 · ClinicalTrials.gov registry record · Phase 3
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
A Phase 3 study, sponsored by Alliance Foundation Trials.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
NCT03009981 is a Phase 3 study that has completed, run by Alliance Foundation Trials. The registered enrollment target is 504 participants.
The verdict
NCT03009981, a Phase 3 study, has completed, sponsored by Alliance Foundation Trials.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
Study Summary
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Interventions
- DRUG Apalutamide
- DRUG Prednisone
- DRUG Abiraterone Acetate
- DRUG LHRH Analogue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03009981
The ClinicalTrials.gov registry entry for NCT03009981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Apalutamide is the first listed.
NCT03009981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03009981 about?
NCT03009981 is a clinical study titled "A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer". This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
What is the current status of trial NCT03009981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2017-03-06. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT03009981?
The interventions under investigation include: Apalutamide (DRUG), Prednisone (DRUG), Abiraterone Acetate (DRUG), LHRH Analogue (DRUG).
Who is sponsoring clinical trial NCT03009981?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.